Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BG Medicine, on behalf of the HRP Initiative, has announced that Takeda Pharmaceutical Company has joined BG Medicine, Merck, AstraZeneca, and Philips as the newest member of the Initiative.
Subscribe to our email newsletter
The HRP Initiative is a pre-competitive industry collaboration that is focused on discovering and developing novel blood tests and imaging methods to find individuals with high-risk plaque disease before the occurrence of the first cardiovascular event.
The HRP Initiative collaborator companies share responsibility for the overall planning and governance of the HRP research activities. They also provide funding for the Initiative in exchange for certain rights to project data, materials and other intellectual property.
Valentin Fuster, cardiologist and chairman of the scientific advisory board for the HRP Initiative and principal investigator of the HRP BioImage Study, said: “The HRP initiative continues to gain momentum as illustrated by Takeda joining forces with Merck, AstraZeneca, Philips and BG Medicine. Recent reports on the limitations of measuring cholesterol as a risk predictor underscore the importance of the HRP initiative to discover and develop novel imaging and blood biomarkers of actual disease.”